OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS

M&A Transactions

M&A Transaction Chart

Viridian publishes weekly data on M&A transactions in the Cannabis/CBD/Psychedelic industries. This data includes information about the buyer and seller (public/private, state/country location), deal size, deal structure (cash, stock, earn-out), pricing, share information, and deal implied valuation.

Week ended 12/30/2022

Week ended 12/30/2022

This Section is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.

M&A Transactions Commentary

Viridian publishes weekly insights on the M&A landscape in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful M&A transactions for that week, and commentary on market conditions, M&A deal structures, target regions for acquirers, and industry sectors ripe for consolidation.

Week ended 12/30/2022

The Only M&A Deal of the Week:

  • On December 27, 2022, Flora Growth Corp. (FLGC: Nasdaq),  a leading all-outdoor cultivator, manufacturer, and distributor of global cannabis products, announced the closing of its acquisition of all outstanding shares of Franchise Global Health (FGH: TSX), a multinational operator in medical cannabis with principal operations in Germany.
    • The $11.0M consideration was paid through the issuance of 43.5M common shares of Flora.
    • The consideration represents a .25x multiple of FGH’s annualized 9-month revenues.
    • The deal establishes a foothold for the distribution of wholesale cannabis products in Europe.
    • FGH, through a subsidiary, holds the first German medical cannabis import and distribution license, granted in 2017.

Week ended 12/30/2022

This is the MA basic

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.